Maqsood Ahmad, MD
Cardiovascular Disease · Milwaukee, WINPI 1639143548
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 129 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Johnson & Johnson accounts for 67.5% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2022 at $469 and has fallen 82.5% since, to $82 in 2025.
Across 129 payments — averaging $13.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$1K
- Novartis$236
- AstraZeneca$68
- Amgen$44
- Bayer$32
- Daiichi Sankyo Inc.$23
- plus $161 from 10 others
What the payments were for
- Food & beverage$1,71799%
- Education$141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 99 | $1,168 |
| Novartis | 12 | $236 |
| AstraZeneca | 4 | $68 |
| Amgen | 2 | $44 |
| Bayer | 1 | $32 |
| Daiichi Sankyo Inc. | 1 | $23 |
| Astellas Pharma US Inc | 1 | $21 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Sanofi Pasteur Inc. | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| Novo Nordisk | 1 | $16 |
| Alnylam Pharmaceuticals Inc. | 1 | $16 |
| Pfizer | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Kestra Medical Technology Services, Inc. | 1 | $13 |
| Lilly USA, LLC | 1 | $13 |
How this compares
$1,731 in reported general payments places this provider in the 60th percentile of 322 cardiovascular disease providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 83 | $118,032 |
| XareltoRivaroxaban | 20 | $18,106 |
| FarxigaDapagliflozin Propanediol | 15 | $10,963 |
| Atorvastatin Calcium | 360 | $2,904 |
| ClopidogrelClopidogrel Bisulfate | 228 | $2,624 |
| Nitroglycerin PatchNitroglycerin | 50 | $2,340 |
| Metoprolol Succinate | 234 | $2,202 |
| Pantoprazole Sodium | 175 | $2,005 |
| Amlodipine Besylate | 313 | $1,781 |
| Losartan Potassium | 156 | $1,301 |
| Carvedilol | 150 | $1,163 |
| Diltiazem 24hr Er (La)Diltiazem Hcl | 14 | $1,081 |
| Potassium Chloride | 104 | $1,068 |
| Pravastatin Sodium | 67 | $1,017 |
| Rosuvastatin Calcium | 71 | $1,006 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $16 | $118,03283 claims |
| Johnson & JohnsonXarelto | $1,168 | $18,10620 claims |
| AstraZenecaFarxiga | $68 | $10,96315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 322 cardiovascular disease providers in Wisconsin.
Other cardiovascular disease in Milwaukee
- Lee BibloMilwaukee$280K
- David GrambowMilwaukee$267K
- Eric RobertsMilwaukee$131K
- Renuka JainMilwaukee$131K
- Evgenia RaichlinMilwaukee$73K
- Prakash ShahMilwaukee$51K
- Sisir SiddamsettiMilwaukee$44K
- Manmeet SinghMilwaukee$39K
- Jordan SwisherMilwaukee$36K
- Christian BreburdaMilwaukee$35K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.